Multivariate analysis of survival
| Characteristic . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| HCV infection | ||||||
| Negative | 1.00 | Ref | 1.00 | Ref | ||
| Positive | 0.97 | 0.59-1.60 | NS | 1.22 | 0.69-2.15 | NS |
| Sex | ||||||
| Male | 1.00 | Ref | 1.00 | Ref | ||
| Female | 1.47 | 0.98-2.22 | NS | 1.44 | 0.88-2.37 | NS |
| Age, y | ||||||
| 20-60 | 1.00 | Ref | 1.00 | Ref | ||
| > 60 | 1.02 | 1.01-1.04 | .01 | 1.03 | 1.01-1.06 | .007 |
| LDH | ||||||
| Normal | 1.00 | Ref | 1.00 | Ref | ||
| > Normal | 1.16 | 0.72-1.87 | NS | 1.37 | 0.77-2.43 | NS |
| PS | ||||||
| 0-1 | 1.00 | Ref | 1.00 | Ref | ||
| 2-4 | 1.28 | 1.04-1.59 | .02 | 1.16 | 0.89-1.51 | NS |
| Extranodal sites | ||||||
| 0 or 1 | 1.00 | Ref | 1.00 | Ref | ||
| 2 | 0.77 | 0.45-1.30 | NS | 0.87 | 0.45-1.68 | NS |
| Stage | ||||||
| I, II | 1.00 | Ref | 1.00 | Ref | ||
| III, IV | 1.64 | 1.28-2.11 | < .001 | 1.67 | 1.20-2.32 | .002 |
| Characteristic . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| HCV infection | ||||||
| Negative | 1.00 | Ref | 1.00 | Ref | ||
| Positive | 0.97 | 0.59-1.60 | NS | 1.22 | 0.69-2.15 | NS |
| Sex | ||||||
| Male | 1.00 | Ref | 1.00 | Ref | ||
| Female | 1.47 | 0.98-2.22 | NS | 1.44 | 0.88-2.37 | NS |
| Age, y | ||||||
| 20-60 | 1.00 | Ref | 1.00 | Ref | ||
| > 60 | 1.02 | 1.01-1.04 | .01 | 1.03 | 1.01-1.06 | .007 |
| LDH | ||||||
| Normal | 1.00 | Ref | 1.00 | Ref | ||
| > Normal | 1.16 | 0.72-1.87 | NS | 1.37 | 0.77-2.43 | NS |
| PS | ||||||
| 0-1 | 1.00 | Ref | 1.00 | Ref | ||
| 2-4 | 1.28 | 1.04-1.59 | .02 | 1.16 | 0.89-1.51 | NS |
| Extranodal sites | ||||||
| 0 or 1 | 1.00 | Ref | 1.00 | Ref | ||
| 2 | 0.77 | 0.45-1.30 | NS | 0.87 | 0.45-1.68 | NS |
| Stage | ||||||
| I, II | 1.00 | Ref | 1.00 | Ref | ||
| III, IV | 1.64 | 1.28-2.11 | < .001 | 1.67 | 1.20-2.32 | .002 |
Ref indicates reference; and NS, not significant.